Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of RSV Vaccine LID cp ΔM2-2 in Infants
NCT02890381Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2016
- Primary completion
- Apr 2017
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing RSV LID cp ΔM2-2 Vaccine with Placebo (2 arms). Primary endpoints: Number of Participants With Solicited Adverse Events, Number of Participants With Unsolicited Adverse Events and 6 more. Started Oct 2016; status: terminated.
02
Drugs
RSV LID cp ΔM2-2
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02890381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02890381.